Vnitr Lek 2010, 56(1):11-13

Cancer and deep vein thrombosis - editorial

J. Malý
II. interní klinika Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc.

Cancer patients with thrombosis and haemorrhagy are a particular problem. They have an increased risk of deep vein thrombosis and pulmonary embolism, and they're more prone to bleeding from anticoagulant therapy. So it really is a dilemma. Clinical research has shown that prevention and initial therapy can consist of subcutaneous low-molecular-weight heparin for an initial period, followed by long-term anticoagulant therapy.

Keywords: cancer; deep vein thrombosis; long-term anticoagulant therapy

Received: July 7, 2009; Published: January 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Malý J. Cancer and deep vein thrombosis - editorial. Vnitr Lek. 2010;56(1):11-13.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Trousseau A. Phlegmasia alba dolens. In: J. B. Balliére et al. Anonymous Médical de Hotel-Dieu de Paris. Paris 1865: 652-695.
    2. Bouillaud SD. Obliteration des veines et de son influence sur la formation des hydropisies partielles: consideration sur la hydropisies passive et general. Arch Gen Med 1823; 1: 188-204.
    3. Büller H, TenCate JW. Primary venous thromboembolism and cancer screening. Editorial. N Engl J Med 1998; 338: 1221-1222. Go to original source... Go to PubMed...
    4. Malý J, Dulíček P, Blažek M et al. Trombofilní stavy - laboratorní a klinická diagnostika. Interv Akut Kardiol 2007; 6 (Suppl B): B11-B16.
    5. Prandoni P, Samama MM. Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients. Brit J Haematol 2008; 141: 587-597. Go to original source... Go to PubMed...
    6. Kakkar VV. Prevention and management of venous thrombosis. Br Med Bull 1994; 50: 871-903. Go to original source... Go to PubMed...
    7. Levine M. Treatment of Thrombotic Disorders in Cancer Patients. Haemostasis 1997; 27 (Suppl 1): 38-43. Go to original source... Go to PubMed...
    8. Prins MH. Cancer and thrombosis. Proc. Symposium Deep vein thrombosis. State of the art - Geneve 1999.
    9. Widimský J, Malý J, Eliáš P et al. Doporučení diagnostiky, léčby a prevence plicní embolie, verze 2007. Vnitř Lék 2008; 54 (Suppl 1): S25-S72.
    10. Malý J, Dulíček P, Penka M et al. Prevence žilní tromboembolické nemoci ve vnitřním lékařství a v neurologii. Vnitř Lék 2006; 52 (Suppl 1): 63-67. Go to PubMed...
    11. Prandoni P et al. Deep vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128-1233. Go to original source... Go to PubMed...
    12. Le Gal G, Righini M, Roy PM et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med 2006; 144: 165-171. Go to original source... Go to PubMed...
    13. Kucher N, Koo S, Quirit R et al. Electronic alert to prevent venous thromboembolism among hospitalized patients. N Engl J Med 2005; 352: 969-972. Go to original source... Go to PubMed...
    14. Hirsh J, Guyatt G, Albers GW et al. American College of Chest Physicians. Evidence-based clinical practice guidelines (8th ed). Executive summary. Chest 2008; 133 (Suppl): 71S-109S. Go to original source...
    15. Lee AY, Levine MN, Baker RI et al. Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153. Go to original source... Go to PubMed...
    16. Kakkar AK, Levine MN, Kadziola Z et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 1944-1948. Go to original source... Go to PubMed...
    17. Klerk CP, Smorenburg SM, Otten HM et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23: 2130-2135. Go to original source... Go to PubMed...
    18. Niers TM, Di Nisio M, Klerk CP et al. Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study. J Thromb Haemost 2007; 5: 1878-1882. Go to original source... Go to PubMed...
    19. Kakkar AK. Current use of venous thromboembolism prophylaxis in cancer patients. Clin Adv Hematol Oncol 2009; 7: 231-233.
    20. Malý J. Délka antikoagulační léčby a riziko recidiv u TEN - editorial. Vnitř Lék 2007; 53: 629-631. Go to PubMed...
    21. Meyer G, Marjanovic Z, Valcke J et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162: 1729-1735. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.